To evaluate performance of a ctDNA assay after incorporation of patient tumor and peripheral blood mononuclear cells. To model the cost effectiveness of the use of ctDNA versus standard of care in this setting. To characterize genomic profiles associated with recurrence using a ctDNA assay in patients with resected stage IIA colon cancer. To describe the association of quantitative ctDNA levels with time to event outcomes (RFS, OS, and TTR). To estimate the rate of compliance with adjuvant chemotherapy and/or active surveillance for patients with resected stage IIA colon cancer. To estimate time-to-event outcomes (overall survival, recurrence-free survival, and time to recurrence ) by ctDNA marker status and treatment for patients with resected stage IIA colon cancer. To describe the prevalence of detectable ctDNA in patients with stage IIA colon cancer following surgical resection. To compare recurrence-free survival (RFS) in "ctDNA detected" patients treated with or without adjuvant chemotherapy following resection of stage IIA colon cancer. To compare the rate of ctDNA clearance in "ctDNA detected" patients treated with or without adjuvant chemotherapy following resection of stage IIA colon cancer.
0 Comments
Leave a Reply. |